Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project.

Wesselman LMP, Doorduijn AS, de Leeuw FA, Verfaillie SCJ, van Leeuwenstijn-Koopman M, Slot RER, Kester MI, Prins ND, van de Rest O, de van der Schueren MAE, Scheltens P, Sikkes SAM, van der Flier WM.

Nutrients. 2019 May 11;11(5). pii: E1057. doi: 10.3390/nu11051057.

2.

High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline.

Verfaillie SCJ, Witteman J, Slot RER, Pruis IJ, Vermaat LEW, Prins ND, Schiller NO, van de Wiel M, Scheltens P, van Berckel BNM, van der Flier WM, Sikkes SAM.

Neuropsychologia. 2019 May 7;131:184-192. doi: 10.1016/j.neuropsychologia.2019.05.006. [Epub ahead of print]

3.

Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.

Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, Windhorst AD, Wolters EE, Yaqub M, Prins ND, Lammertsma AA, Scheltens P, van der Flier WM, van Berckel BNM.

Neurobiol Aging. 2019 Jul;79:50-58. doi: 10.1016/j.neurobiolaging.2019.02.020. Epub 2019 Mar 8.

4.

Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study

Leeuwis AE, Weaver NA, Biesbroek JM, Exalto LG, Kuijf HJ, Hooghiemstra AM, Prins ND, Scheltens P, Barkhof F, van der Flier WM, Biessels GJ; TRACE-VCI study group.

J Psychiatry Neurosci. 2019 Jul 1;44(4):E1-E10.

5.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

6.

How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study.

Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Leeuwis AE, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ; behalf of the TRACE-VCI study group.

J Alzheimers Dis. 2019;68(3):1273-1286. doi: 10.3233/JAD-180696.

PMID:
30909212
7.

Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment.

Ferro DA, van den Brink H, Exalto LG, Boomsma JMF, Barkhof F, Prins ND, van der Flier WM, Biessels GJ; TRACE-VCI study group.

Neurology. 2019 Apr 2;92(14):e1558-e1566. doi: 10.1212/WNL.0000000000007250. Epub 2019 Mar 8.

PMID:
30850444
8.

The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus.

Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ; TRACE-VCI study group.

J Alzheimers Dis. 2019;68(1):311-322. doi: 10.3233/JAD-180914.

PMID:
30775988
9.

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project.

Verfaillie SCJ, Timmers T, Slot RER, van der Weijden CWJ, Wesselman LMP, Prins ND, Sikkes SAM, Yaqub M, Dols A, Lammertsma AA, Scheltens P, Ossenkoppele R, van Berckel BNM, van der Flier WM.

Front Aging Neurosci. 2019 Jan 25;11:7. doi: 10.3389/fnagi.2019.00007. eCollection 2019.

10.

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND.

Alzheimers Res Ther. 2018 Oct 12;10(1):107. doi: 10.1186/s13195-018-0431-6.

11.

Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study.

Leeuwis AE, Smith LA, Melbourne A, Hughes AD, Richards M, Prins ND, Sokolska M, Atkinson D, Tillin T, Jäger HR, Chaturvedi N, van der Flier WM, Barkhof F.

Front Aging Neurosci. 2018 Sep 18;10:279. doi: 10.3389/fnagi.2018.00279. eCollection 2018.

12.

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.

Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM.

Ann Neurol. 2018 Nov;84(5):648-658. doi: 10.1002/ana.25334. Epub 2018 Oct 4.

13.

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.

Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM.

Alzheimers Res Ther. 2018 Aug 7;10(1):76. doi: 10.1186/s13195-018-0390-y.

14.

Survival in memory clinic cohort is short, even in young-onset dementia.

Rhodius-Meester HFM, Tijms BM, Lemstra AW, Prins ND, Pijnenburg YAL, Bouwman F, Scheltens P, van der Flier WM.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):726-728. doi: 10.1136/jnnp-2018-318820. Epub 2018 Jul 25. No abstract available.

15.

Microbleeds are associated with depressive symptoms in Alzheimer's disease.

Leeuwis AE, Prins ND, Hooghiemstra AM, Benedictus MR, Scheltens P, Barkhof F, van der Flier WM.

Alzheimers Dement (Amst). 2017 Dec 6;10:112-120. doi: 10.1016/j.dadm.2017.11.006. eCollection 2018.

16.

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline.

Verfaillie SCJ, Slot RER, Dicks E, Prins ND, Overbeek JM, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM, Tijms BM.

Hum Brain Mapp. 2018 Aug;39(8):3143-3151. doi: 10.1002/hbm.24065. Epub 2018 Mar 30.

17.

Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.

Leijenaar JF, Groeneveld GJ, van der Flier WM, Scheltens P, Klaassen ES, Weinstein HC, Biessels GJ, Barkhof F, Prins ND.

JMIR Res Protoc. 2018 Mar 20;7(3):e80. doi: 10.2196/resprot.9192.

18.

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging.

Leijenaar JF, van Maurik IS, Kuijer JPA, van der Flier WM, Scheltens P, Barkhof F, Prins ND.

Alzheimers Dement (Amst). 2017 Nov 2;9:76-83. doi: 10.1016/j.dadm.2017.10.001. eCollection 2017.

19.

The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design.

Bertens D, Tijms BM, Vermunt L, Prins ND, Scheltens P, Visser PJ.

Alzheimers Dement (N Y). 2017 Sep 21;3(4):513-523. doi: 10.1016/j.trci.2017.08.005. eCollection 2017 Nov.

20.

Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment.

Leeuwis AE, Hooghiemstra AM, Amier R, Ferro DA, Franken L, Nijveldt R, Kuijer JPA, Bronzwaer AGT, van Lieshout JJ, Rietberg MB, Veerbeek JM, Huijsmans RJ, Backx FJG, Teunissen CE, Bron EE, Barkhof F, Prins ND, Shahzad R, Niessen WJ, de Roos A, van Osch MJP, van Rossum AC, Biessels GJ, van der Flier WM; Heart Brain Connection study group.

Alzheimers Dement (N Y). 2017 Mar 6;3(2):157-165. doi: 10.1016/j.trci.2017.02.002. eCollection 2017 Jun.

21.

The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria.

Krudop WA, Dols A, Kerssens CJ, Eikelenboom P, Prins ND, Möller C, Schouws S, Rhebergen D, van Exel E, van der Flier WM, Sikkes S, Scheltens P, Stek ML, Pijnenburg YAL.

J Alzheimers Dis. 2017;60(3):959-975. doi: 10.3233/JAD-170608.

PMID:
28984605
22.

Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study.

Boomsma JMF, Exalto LG, Barkhof F, van den Berg E, de Bresser J, Heinen R, Koek HL, Prins ND, Scheltens P, Weinstein HC, van der Flier WM, Biessels GJ.

JMIR Res Protoc. 2017 Apr 19;6(4):e60. doi: 10.2196/resprot.6864.

23.

Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders.

Vijverberg EG, Dols A, Krudop WA, Del Campo Milan M, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, Teunissen CE, Pijnenburg YA.

Alzheimers Dement (Amst). 2017 Mar 2;7:99-106. doi: 10.1016/j.dadm.2017.01.009. eCollection 2017.

24.

The effect of hippocampal function, volume and connectivity on posterior cingulate cortex functioning during episodic memory fMRI in mild cognitive impairment.

Papma JM, Smits M, de Groot M, Mattace Raso FU, van der Lugt A, Vrooman HA, Niessen WJ, Koudstaal PJ, van Swieten JC, van der Veen FM, Prins ND.

Eur Radiol. 2017 Sep;27(9):3716-3724. doi: 10.1007/s00330-017-4768-1. Epub 2017 Mar 13.

25.

Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests.

Van Mierlo LD, Wouters H, Sikkes SA, Van der Flier WM, Prins ND, Bremer JA, Koene T, Van Hout HP.

J Alzheimers Dis. 2017;56(1):249-259. doi: 10.3233/JAD-160566.

26.

Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease.

Leeuwis AE, Benedictus MR, Kuijer JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM.

Alzheimers Dement. 2017 May;13(5):531-540. doi: 10.1016/j.jalz.2016.08.013. Epub 2016 Sep 28.

PMID:
27693109
27.

Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes.

Vijverberg EG, Wattjes MP, Dols A, Krudop WA, Möller C, Peters A, Kerssens CJ, Gossink F, Prins ND, Stek ML, Scheltens P, van Berckel BN, Barkhof F, Pijnenburg YA.

J Alzheimers Dis. 2016 Jun 30;53(4):1287-97. doi: 10.3233/JAD-160285.

PMID:
27372646
28.

Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease.

Benedictus MR, Leeuwis AE, Binnewijzend MA, Kuijer JP, Scheltens P, Barkhof F, van der Flier WM, Prins ND.

Eur Radiol. 2017 Mar;27(3):1169-1175. doi: 10.1007/s00330-016-4450-z. Epub 2016 Jun 22.

29.

Schizophrenia as a mimic of behavioral variant frontotemporal dementia.

Kerssens CJ, Krudop WA, Prins ND, van Berckel BN, Rozemuller A, Seeley WW, Scheltens P, Stek ML, Pijnenburg YA.

Neurocase. 2016 Jun;22(3):285-8. doi: 10.1080/13554794.2016.1187178. Epub 2016 May 25.

30.

Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome.

Vijverberg EG, Dols A, Krudop WA, Peters A, Kerssens CJ, van Berckel BN, Wattjes MP, Barkhof F, Gossink F, Prins ND, Stek ML, Scheltens P, Pijnenburg YA.

Dement Geriatr Cogn Disord. 2016;41(3-4):210-9. doi: 10.1159/000444849. Epub 2016 May 5.

31.

Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia.

Gossink FT, Dols A, Krudop WA, Sikkes SA, Kerssens CJ, Prins ND, Scheltens P, Stek ML, Pijnenburg YA.

J Alzheimers Dis. 2016;51(4):1249-56. doi: 10.3233/JAD-151198.

PMID:
26967225
32.

Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort.

Krudop WA, Dols A, Kerssens CJ, Prins ND, Möller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Sikkes SA, Stek ML, Pijnenburg YA.

Dement Geriatr Cogn Disord. 2016;41(1-2):16-26. doi: 10.1159/000441023. Epub 2015 Oct 17.

PMID:
26473985
33.

White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline.

Benedictus MR, van Harten AC, Leeuwis AE, Koene T, Scheltens P, Barkhof F, Prins ND, van der Flier WM.

Stroke. 2015 Sep;46(9):2661-4. doi: 10.1161/STROKEAHA.115.009475. Epub 2015 Jul 14.

PMID:
26173729
34.

Cerebral perfusion in the predementia stages of Alzheimer's disease.

Binnewijzend MA, Benedictus MR, Kuijer JP, van der Flier WM, Teunissen CE, Prins ND, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F.

Eur Radiol. 2016 Feb;26(2):506-14. doi: 10.1007/s00330-015-3834-9. Epub 2015 Jun 5.

35.

Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach.

Krudop WA, Kerssens CJ, Dols A, Prins ND, Möller C, Schouws S, van der Flier WM, Scheltens P, Sikkes S, Stek ML, Pijnenburg YA.

Am J Geriatr Psychiatry. 2015 Oct;23(10):1056-66. doi: 10.1016/j.jagp.2015.04.002. Epub 2015 Apr 7.

PMID:
25921226
36.

Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study.

Benedictus MR, Prins ND, Goos JD, Scheltens P, Barkhof F, van der Flier WM.

JAMA Neurol. 2015 May;72(5):539-45. doi: 10.1001/jamaneurol.2015.14.

PMID:
25798556
37.

White matter hyperintensities, cognitive impairment and dementia: an update.

Prins ND, Scheltens P.

Nat Rev Neurol. 2015 Mar;11(3):157-65. doi: 10.1038/nrneurol.2015.10. Epub 2015 Feb 17. Review.

PMID:
25686760
38.

The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.

Prins ND, van der Flier WA, Knol DL, Fox NC, Brashear HR, Nye JS, Barkhof F, Scheltens P.

Alzheimers Res Ther. 2014 Jul 21;6(4):47. doi: 10.1186/alzrt275. eCollection 2014.

39.

Trajectories of cognitive decline in different types of dementia.

Smits LL, van Harten AC, Pijnenburg YA, Koedam EL, Bouwman FH, Sistermans N, Reuling IE, Prins ND, Lemstra AW, Scheltens P, van der Flier WM.

Psychol Med. 2015 Apr;45(5):1051-9. doi: 10.1017/S0033291714002153. Epub 2014 Sep 17.

PMID:
25229325
40.

Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic.

Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, Scheltens P, van der Flier WM.

Alzheimers Dement. 2015 May;11(5):523-32. doi: 10.1016/j.jalz.2014.05.1753. Epub 2014 Aug 22.

PMID:
25156643
41.

Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease.

Benedictus MR, Binnewijzend MAA, Kuijer JPA, Steenwijk MD, Versteeg A, Vrenken H, Scheltens P, Barkhof F, van der Flier WM, Prins ND.

Neurobiol Aging. 2014 Dec;35(12):2665-2670. doi: 10.1016/j.neurobiolaging.2014.06.001. Epub 2014 Jun 13.

PMID:
25018106
42.

Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies.

Binnewijzend MA, Kuijer JP, van der Flier WM, Benedictus MR, Möller CM, Pijnenburg YA, Lemstra AW, Prins ND, Wattjes MP, van Berckel BN, Scheltens P, Barkhof F.

Eur Radiol. 2014 Sep;24(9):2326-33. doi: 10.1007/s00330-014-3172-3. Epub 2014 Jul 5.

PMID:
24996793
43.

Disturbed phase relations in white matter hyperintensity based vascular dementia: an EEG directed connectivity study.

van Straaten EC, den Haan J, de Waal H, van der Flier WM, Barkhof F, Prins ND, Stam CJ.

Clin Neurophysiol. 2015 Mar;126(3):497-504. doi: 10.1016/j.clinph.2014.05.018. Epub 2014 Jun 4.

PMID:
24969377
44.

Prevalence of cortical superficial siderosis in a memory clinic population.

Zonneveld HI, Goos JD, Wattjes MP, Prins ND, Scheltens P, van der Flier WM, Kuijer JP, Muller M, Barkhof F.

Neurology. 2014 Feb 25;82(8):698-704. doi: 10.1212/WNL.0000000000000150. Epub 2014 Jan 29.

PMID:
24477113
45.

Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future.

Prins ND, Scheltens P.

Alzheimers Res Ther. 2013 Nov 11;5(6):56. doi: 10.1186/alzrt220. eCollection 2013. Review.

46.

Cerebral small vessel disease affects white matter microstructure in mild cognitive impairment.

Papma JM, de Groot M, de Koning I, Mattace-Raso FU, van der Lugt A, Vernooij MW, Niessen WJ, van Swieten JC, Koudstaal PJ, Prins ND, Smits M.

Hum Brain Mapp. 2014 Jun;35(6):2836-51. doi: 10.1002/hbm.22370. Epub 2013 Sep 23.

PMID:
24115179
47.

Amyloid imaging in clinical trials.

Ossenkoppele R, Prins ND, van Berckel BN.

Alzheimers Res Ther. 2013 Aug 14;5(4):36. doi: 10.1186/alzrt195. eCollection 2013.

48.

Serum proteomics in amnestic mild cognitive impairment.

Ijsselstijn L, Papma JM, Dekker LJ, Calame W, Stingl C, Koudstaal PJ, Prins ND, Sillevis Smitt PA, Luider TM.

Proteomics. 2013 Aug;13(16):2526-33. doi: 10.1002/pmic.201200190. Epub 2013 Jul 19.

PMID:
23868823
49.

Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study.

Krudop WA, Kerssens CJ, Dols A, Prins ND, Möller C, Schouws S, Barkhof F, van Berckel BN, Teunissen CE, van der Flier WM, Scheltens P, Stek ML, Pijnenburg YA.

Am J Geriatr Psychiatry. 2014 Jul;22(7):735-40. doi: 10.1016/j.jagp.2013.02.002. Epub 2013 Jun 25.

PMID:
23806681
50.

Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease.

Benedictus MR, Goos JD, Binnewijzend MA, Muller M, Barkhof F, Scheltens P, Prins ND, van der Flier WM.

Neurobiol Aging. 2013 Nov;34(11):2488-94. doi: 10.1016/j.neurobiolaging.2013.04.023. Epub 2013 May 31.

PMID:
23731952

Supplemental Content

Loading ...
Support Center